Compounds in 'monster' radish could help tame cardiovascular disease

Step aside carrots, onions and broccoli. The newest heart-healthy vegetable could be a gigantic, record-setting radish. In a study appearing in ACS' Journal of Agricultural and Food Chemistry, scientists report that compounds found in the Sakurajima Daikon, or "monster," radish could help protect coronary blood vessels and potentially prevent heart disease and stroke. The finding could lead to the discovery of similar substances in other vegetables and perhaps lead to new drug treatments.

Grown for centuries in Japan, the Sakurajima Daikon is one of the Earth's most massive vegetables. In 2003, the Guinness Book of World Records certified a Sakurajima weighing nearly 69 pounds as the world's heaviest radish. Radishes are good sources of antioxidants and reportedly can reduce high blood pressure and the threat of clots, a pair of risk factors for heart attack and stroke. But to date, no studies have directly compared the heart-health benefits of the Sakurajima Daikon to other radishes. To address this knowledge gap, Katsuko Kajiya and colleagues sought to find out what effects this radish would have on nitric oxide production, a key regulator of coronary blood vessel function, and to determine its underlying mechanisms.

The researchers exposed human and pig vascular endothelial cells to extracts from Sakurajima Daikon and smaller radishes. Using fluorescence microscopy and other analytical techniques, the research team found the Sakurajima Daikon radish induced more nitric oxide production in these vascular cells than a smaller Japanese radish. They also identified trigonelline, a plant hormone, as the active component in Sakurajima Daikon that appears to promote a cascade of changes in coronary blood vessels resulting improved nitric oxide production.

Rei Kuroda, Kimiko Kazumura, Miki Ushikata, Yuji Minami, Katsuko Kajiya.
Elucidating the Improvement in Vascular Endothelial Function from Sakurajima Daikon and Its Mechanism of Action: A Comparative Study with Raphanus sativus.
J. Agric. Food Chem., doi: 10.1021/acs.jafc.8b01750.

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...